Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways

Jing,Guifang; Yu,Fang; Xue,Huandong

doi:10.3892/ol.2022.13290

Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways

Authors:
- Guifang Jing
- Fang Yu
- Huandong Xue
View Affiliations

Affiliations: Department of Dermatology, Affiliated Hospital of Chifeng University, Chifeng, Inner Mongolia Autonomous Region 024005, P.R. China
Published online on: April 13, 2022 https://doi.org/10.3892/ol.2022.13290
Article Number: 170
Copyright: © Jing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma seriously threatens public health and lowers the quality of life of the affected subjects. The present study was designed to explore the effects of tepotinib, a selective tyrosine kinase inhibitor of MET proto‑oncogene, receptor tyrosine kinase (MET), on the progression of melanoma. Firstly, MTT assays were used to detect the proliferation of tepotinib‑treated WM451 cells. The cell invasive and migratory activities were assessed using Transwell and wound healing assays, respectively. In addition, TUNEL staining was employed to determine cell apoptosis. Western blot analysis was utilized for the evaluation of the expression levels of apoptotic and epithelial‑mesenchymal transition‑related proteins, as well as of proteins involved in the PI3K/AKT signaling pathway. Subsequently, hepatocyte growth factor (HGF), a natural agonist of MET, was administered to WM451 cells to unravel the detailed mechanism of action of tepotinib in melanoma. The results indicated that the proliferation of WM451 cells was significantly decreased by tepotinib treatment. The inhibitory effects of tepotinib on the proliferation of WM451 cells occurred in a concentration‑dependent manner. In addition, the migratory and invasive activities of WM451 cells were significantly suppressed following tepotinib treatment. It was also shown that tepotinib exhibited promotive effects on the induction of apoptosis of WM451 cells. Moreover, activation of MET and PI3K/AKT signaling pathways may be blocked by tepotinib treatment, whereas addition of HGF to the cells reversed the effects of tepotinib treatment on the malignant progression of WM451 cells. In conclusion, the data demonstrated that tepotinib suppressed the proliferation, invasion and migration of melanoma cells, whereas it could also induce their apoptosis. This evidence may provide a new perspective for the improvement of malignant melanoma.

View Figures

View References

1	Bai R, Huang H, Li M and Chu M: Temporal trends in the incidence and mortality of skin malignant melanoma in China from 1990 to 2019. J Oncol. 24:99898242021.PubMed/NCBI
2	Magro CM, Crowson AN and Mihm MC: Unusual variants of malignant melanoma. Mod Pathol. 19 (Suppl 2):S41–S70. 2006. View Article : Google Scholar : PubMed/NCBI
3	Koh HK: Cutaneous melanoma. N Engl J Med. 325:171–182. 1991. View Article : Google Scholar : PubMed/NCBI
4	Miller AJ and Mihm MC Jr: Melanoma. N Engl J Med. 355:51–65. 2006. View Article : Google Scholar : PubMed/NCBI
5	Arrington JH III, Reed RJ, Ichinose H and Krementz ET: Plantar lentiginous melanoma: A distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol. 1:131–143. 1977. View Article : Google Scholar : PubMed/NCBI
6	Clark WH Jr, From L, Bernardino EA and Mihm MC: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29:705–727. 1969.PubMed/NCBI
7	McGovern VJ: The classification of melanoma and its relationship with prognosis. Pathology. 2:85–98. 1970. View Article : Google Scholar : PubMed/NCBI
8	de Souza CF, Morais AS and Jasiulionis MG: Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract. 2012:1560682012. View Article : Google Scholar : PubMed/NCBI
9	Fecher LA, Cummings SD, Keefe MJ and Alani RM: Toward a molecular classification of melanoma. J Clin Oncol. 25:1606–1620. 2007. View Article : Google Scholar : PubMed/NCBI
10	Somasundaram R, Villanueva J and Herlyn M: Intratumoral heterogeneity as a therapy resistance mechanism: Role of melanoma subpopulations. Adv Pharmacol. 65:335–359. 2012. View Article : Google Scholar : PubMed/NCBI
11	Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, et al: First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res. 26:1237–1246. 2020. View Article : Google Scholar : PubMed/NCBI
12	Friese-Hamim M, Bladt F, Locatelli G, Stammberger U and Blaukat A: The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am J Cancer Res. 7:962–972. 2017.PubMed/NCBI
13	Sohn SH, Sul HJ, Kim B, Kim BJ, Kim HS and Zang DY: Tepotinib inhibits the epithelial-mesenchymal transition and tumor growth of gastric cancers by increasing GSK3beta, E-cadherin, and mucin 5AC and 6 levels. Int J Mol Sci. 21:60272020. View Article : Google Scholar : PubMed/NCBI
14	Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler G, Meyring M, Dorsch D, Jaehrling F, et al: EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res. 19:2941–2951. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bladt F, Friese-Hamim M, Ihling C, Wilm C and Blaukat A: The c-met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models. Cancers (Basel). 6:1736–1752. 2014. View Article : Google Scholar : PubMed/NCBI
16	De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K and Bottaro DP: Targeting the hepatocyte growth factor/Met pathway in cancer. Biochem Soc Trans. 45:855–870. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cao HH, Cheng CY, Su T, Fu XQ, Guo H, Li T, Tse AKW, Kwan HY, Yu H and Yu ZL: Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer. 14:1032015. View Article : Google Scholar : PubMed/NCBI
18	Xie Y, Shi X, Sheng K, Han G, Li W, Zhao Q, Jiang B, Feng J, Li J and Gu Y: PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 19:783–791. 2019.PubMed/NCBI
19	Tan AC: Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 11:511–518. 2020. View Article : Google Scholar : PubMed/NCBI
20	Davies MA: The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of print). View Article : Google Scholar
22	Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H, Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer. 16:1182017. View Article : Google Scholar : PubMed/NCBI
23	Pistritto G, Trisciuoglio D, Ceci C, Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
24	Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Meerbeeck JV, et al: Tepotinib in non-small-cell lung cancer with met exon 14 skipping mutations. N Engl J Med. 383:931–943. 2020. View Article : Google Scholar : PubMed/NCBI
25	Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and Cho MK: Expression of the c-Met proteins in malignant skin cancers. Ann Dermatol. 23:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
26	Recio JA and Merlino G: Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene. 21:1000–1008. 2002. View Article : Google Scholar : PubMed/NCBI
27	Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M and Merlino G: c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 58:5157–5167. 1998.PubMed/NCBI
28	Beuret L, Flori E, Denoyelle C, Bille K, Busca R, Picardo M, Bertolotto C and Ballotti R: Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem. 282:14140–14147. 2007. View Article : Google Scholar : PubMed/NCBI
29	Cheng JC, Chou CH, Kuo ML and Hsieh CY: Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene. 25:7009–7018. 2006. View Article : Google Scholar : PubMed/NCBI
30	Chen WY, Xu YY and Zhang XY: Targeting GOLM1 by microRNA-200a in melanoma suppresses cell proliferation, invasion and migration via regulating PI3K/Akt signaling pathway and epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci. 23:6997–7007. 2019.PubMed/NCBI
31	Dang N, Meng X, Ma S, Zhang Q, Sun X, Wei J and Huang S: MDA-19 suppresses progression of melanoma via inhibiting the PI3K/Akt pathway. Open Med (Wars). 13:416–424. 2018. View Article : Google Scholar : PubMed/NCBI
32	Wang J, Li L, Liu S, Zhao Y, Wang L and Du G: FOXC1 promotes melanoma by activating MST1R/PI3K/AKT. Oncotarget. 7:84375–84387. 2016. View Article : Google Scholar : PubMed/NCBI
33	Choi EO, Cho EJ, Jeong JW, Park C, Hong SH, Hwang HJ, Moon SK, Son CG, Kim WJ and Choi YH: Baicalein inhibits the migration and invasion of B16F10 mouse melanoma cells through inactivation of the PI3K/Akt signaling pathway. Biomol Ther (Seoul). 25:213–221. 2017. View Article : Google Scholar : PubMed/NCBI
34	Sharma N and Adjei AA: In the clinic: Ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol. 3 (Suppl 1):S37–S50. 2011. View Article : Google Scholar : PubMed/NCBI